A Complete COVID-19 Testing Solution

Superior, rapid detection coupled with an unparalleled delivery platform

Antibody Testing

Why Is Rapid Antigen Testing Important?

As the world’s nations begin to strategize about the safest plan to reopen large drivers of our economy, accurate and real time health information for all individuals is paramount.

We must know who is infected and contagious with COVID-19 to secure our spaces where we gather to work and play.

Testing for the New Reality

The Test That Defines The New Frontier

Our platform technology seeks to detect specific proteins in an individual's saliva, known as antigens, which are specific biomarkers of viruses, such as SARS-CoV-2; the virus that causes COVID-19. Measuring and quantifying the antigens present in an individual could help determine just how contagious the disease is. That's particularly important for a virus like SARS-CoV-2, which appears to be able to spread before an individual exhibits symptoms, or when their symptoms are very mild or not noticeable.

Family Coronavirus Coverage

Testing Is A Priority for Everyone

Antigen testing is a critical tool to help end the crisis by identifying those who are actively contagious and infected with SARS-CoV-2, the virus that causes COVID-19. The Families First Act and CARES Act, will allocate $2.2 trillion in support to individuals and businesses affected by the pandemic and economic downturn.

SARS-CoV-2 Platform Test Steps

Step One: Sample Collection

  • A testing “proctor” hands a small plastic bag to the test taker.
  • Test taker opens the bag and removes the saliva collection tube.
  • Test taker opens app on their mobile device and scans the QR or bar scan on the saliva collection tube, thus connecting their identity to the saliva collection tube.
  • Test taker drools into the saliva collection tube and screws on the top to seal it.

Step Two: Sample Processing

  • Test taker places the saliva collection tube directly into an automated “harness” designed to rapidly collect samples.
  • The saliva tube is pre-loaded with a dry deactivation agent to immediately deactivate the virus.
  • Samples are processed in a continuous flow basis and automatically inserted into a microplate reader.

Step Three: Sample Measuring

  • Microplate reader reads 96 tests and transmits results to a secure cloud based based environment in minutes as well as processing as few as 8 ports in a fraction of that time

Step Four: Digitally Verified Results within 10 minutes

  • Cloud based results immediately transmitted to the test taker and test validator to the extent such data is being immediately employed at the point of collection for approval of the person to proceed.

Environments Served

Configurations designed for “surge scaling” to many thousands of tests per hour as needed.

  • Airports
  • Colleges and Universities
  • Convention Centers
  • Food Processing Plants
  • Hospitals & Large Health Complexes
  • Sporting Arenas
  • Train Stations



Working jointly with our partner Albany Medical College, FluroTest seeks to advance the Platform Technology developed by FluroTech to rapidly detect the presence and viral load (quantity of viral particles per ml), with SARS-CoV-2 (or “COVID-19”) being the initial target pathogen.

The detection of the virus will be enabled by targeting SARS-CoV-2 nucleocapsid antigens. Additionally, the use of harmless virus particles/components (ex. capsid, spike proteins, among others) could allow for the detection of anti-SARS-CoV-2 human antibodies in a patient’s saliva sample, as a part of a multiplex assay, potentially confirming the development of immunity. The goal is to utilize specific fluorescence-labeled antigen/antibodies with the ability to target a specific virus and/or labeled virus components.

FluroTest is presently engaged in clinical trials with partner Toolbox Medical Innovations and plans submissions for Emergency Use Authorization ("EUA") from the U.S. Food and Drug Administration ("FDA") and from Health Canada for an Interim Order Authorization.


FluroTest’s technology development efforts require unique expertise in spectroscopy and fluorescence as well as immunology and virology. This initiative is a collaborative effort between U.S. and Canadian scientists with deep experience in their respective fields.

For immunology and virology expertise, FluroTest has partnered with Albany Medical College’s (AMC) immunology and microbial disease department. AMC is located in the State of New York. The Department’s research team is led by Dr. Dennis Metzger, professor and chair of the department. Dr. Metzger’s research program concentrates on mucosal immune responses and the mechanisms responsible for viral-bacterial synergy in the lung. AMC is in a unique position to begin large scale sample collection and clinical trials which will assist in obtaining regulatory approvals including the FDA.

For fluorescence spectroscopy expertise, the Company is relying on FluroTech’s laboratory at the University of Calgary, led by Dr. Elmar Prenner. Dr. Prenner is the original developer of the technology owned by AB Photonics. Dr. Prenner, a professor at the University of Calgary within the department of Biological Sciences, serves as senior science advisor of FluroTech and brings over 28 years of expertise in fluorescence spectroscopy.